Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fufang Biejiaruangan Combined With Antiviral Therapy for HCC Prevention in Hepatitis B Cirrhosis
NCT07481032Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- HM (Herbal Medicine)
01
Overview
Randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Standard antiviral therapy + Biejia-Ruangan compound with Standard antiviral therapy + Placebo (2 arms). Primary endpoint: Incidence of Hepatocellular Carcinoma at 96 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Fufang Biejia Ruangan
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07481032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07481032.